Nkarta Inc Market Cap ($123.91 Million)
Market Cap & Net Worth: Nkarta Inc (NKTX)
Nkarta Inc market cap. Nkarta Inc (NASDAQ:NKTX) has a market capitalization of $123.91 Million ($123.91 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18213 globally and #4268 in its home market, demonstrating a 1.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nkarta Inc's stock price $1.73 by its total outstanding shares 71624791 (71.62 Million). Also see how efficiently does Nkarta Inc generate cash for how efficiently the company converts equity into cash flow.
Nkarta Inc Market Cap History (2020–2026)
Nkarta Inc market cap history from 2020 to 2026. Data shows change from $4.40 Billion to $123.91 Million (-40.86% CAGR). Check NKTX stock price and chart for real-time trading data and today's change.
Index Memberships
Nkarta Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #498 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1757 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.01% | #233 of 263 |
Weight: Nkarta Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nkarta Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nkarta Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NKTX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11435781.57x
Nkarta Inc's market cap is 11435781.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $4.40 Billion | $385.00 | -$91.36 Million | 11435781.57x | N/A |
Competitor Companies of NKTX by Market Capitalization
Companies near Nkarta Inc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Nkarta Inc for a full breakdown of the balance sheet.
Key companies related to Nkarta Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Nkarta Inc (2020–2026)
Market capitalization of Nkarta Inc from 2020 to today. Between 2020 and today, Nkarta Inc's market cap moved from $4.40 Billion to $ 123.91 Million, with a yearly change of -40.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $123.91 Million | -6.49% |
| 2025 | $132.51 Million | -25.70% |
| 2024 | $178.35 Million | -62.27% |
| 2023 | $472.72 Million | +10.18% |
| 2022 | $429.03 Million | -60.98% |
| 2021 | $1.10 Billion | -75.03% |
| 2020 | $4.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Nkarta Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $123.91 Million USD |
| MoneyControl | $123.91 Million USD |
| MarketWatch | $123.91 Million USD |
| marketcap.company | $123.91 Million USD |
| Reuters | $123.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more